The Technical Analyst
Apollo Endosurgery Inc [APEN]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Apollo Endosurgery Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $10.00
America/New_York / 3 apr 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 579.72 mill |
| EPS: | -1.060 |
| P/E: | -9.43 |
| Earnings Date: | Jul 31, 2023 |
| SharesOutstanding: | 57.97 mill |
| Avg Daily Volume: | 1.330 mill |
| RATING 2023-04-11 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.43 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -9.43 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 9.96 - 10.04 ( +/- 0.39%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-04-04 | Mcgaughy R Kent Jr | Sell | 400 675 | Common Stock |
| 2023-04-04 | Mcgaughy R Kent Jr | Sell | 38 667 | Stock Option (Right to Buy) |
| 2023-04-04 | Cpmg Inc | Sell | 400 675 | Common Stock |
| 2023-04-04 | Barr John R | Sell | 44 082 | Common Stock |
| 2023-04-04 | Barr John R | Sell | 5 271 | Non-Qualified Stock Option (right to buy) |
| INSIDER POWER |
|---|
| -15.53 |
| Last 98 transactions |
| Buy: 5 638 377 | Sell: 4 907 735 |
Forecast:
01:40 - $10.51
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.00 (0.00% ) |
| Volume | 1.640 mill |
| Avg. Vol. | 1.330 mill |
| % of Avg. Vol | 123.28 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For APEN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
APEN
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Last 10 Buy Signals
Latest Press Releases
2022-11-29 18:52:00 - Press Release
Apollo Endosurgery Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Apollo Endosurgery, Inc. - Apen
New orleans--( business wire )--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of apollo endosurgery, inc. (nasdaqgm: apen) to boston scientific corporation (nyse: bsx). under the terms of the proposed transaction, shareholders of apollo will receive only $10.00 in cash for each share of apollo that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the company.
2022-11-29 17:10:00 - Press Release
Shareholder Alert: Weiss Law Investigates Apollo Endosurgery, Inc.
New york , nov. 29, 2022 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of apollo endosurgery, inc. ("apollo endosurgery" or the "company") (nasdaq: apen), in connection with the proposed acquisition of the company by boston scientific corporation (nyse: bsx). under the terms of the merger agreement, the company's shareholders will receive $10.00 in cash for each share of apollo endosurgery common stock owned.
2022-11-29 07:00:00 - Press Release
Boston Scientific Announces Agreement To Acquire Apollo Endosurgery, Inc.
Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures marlborough, mass. , nov. 29, 2022 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced it has entered into a definitive agreement to acquire apollo endosurgery, inc. (nasdaq: apen) for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million.1 the apollo endosurgery product portfolio includes devices used during endoluminal surgery (els) procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity.
2022-11-29 07:00:00 - Press Release
Apollo Endosurgery To Be Acquired By Boston Scientific
Boston scientific to acquire apollo for $10.00 per share in cash austin, tx / accesswire / november 29, 2022 / apollo endosurgery, inc. ("apollo") (nasdaq:apen), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it has entered into a definitive merger agreement to be acquired by boston scientific corporation ("boston scientific"), a global medical technology leader, in an all-cash transaction with an enterprise value of approximately $615 million.[1] this transaction has been unanimously approved by the apollo board of directors.
2022-10-18 08:00:00 - Press Release
Apollo Endosurgery To Report Third Quarter Results On November 1, 2022
Austin, tx / accesswire / october 18, 2022 / apollo endosurgery, inc. ("company" or "apollo") (nasdaq:apen), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the company is scheduled to release financial results for the third quarter ended september 30, 2022 on tuesday, november 1, 2022, after market close. in conjunction with the release, apollo will host a live webcast audio call with presentation slides at 3:30 p.m.
Latest News
2022-11-29 12:00:17 - Market Watch
Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham
Boston Scientific Corp.'s BSX, +0.88% $615 million acquisition of Apollo Endosurgery Inc. APEN, +65.50% announced earlier is complementary to the former's endoscopy franchise, as it leverages its gastroenterologist call point while offering the potential for it to expand into surgical endoscopy and bariatric surgery, Needham analysts aid Tuesday. The deal is expected to have no material impact on Boston Scientific's 2023 per-share earnings but to boost it after that.
2022-11-29 10:50:02 - Schaeffers Research
Apollo Endosurgery Stock Soars on Buyout Buzz
Apollo Endosurgery Inc (NASDAQ:APEN) stock is soaring, up 63.4% at $9.80 at last glance, after news that Boston Scientific Corp (BSX) will acquire the medical equipment name for $417 million.
2022-11-29 07:13:54 - Market Watch
Boston Scientific to acquire Apollo Endosurgery for $615 million in cash
Boston Scientific Corp. BSX, -0.82% said Tuesday it has agreed to acquire Apollo Endosurgery Inc. APEN, for $10 a share, or about $615 million in cash. The news sent Apollo's stock, which closed Monday at $6, up 61% in premarket trade.
2022-11-01 22:18:05 - Seeking Alpha
Apollo Endosurgery, Inc. (APEN) Q3 2022 Earnings Call Transcript
Apollo Endosurgery, Inc. (NASDAQ:APEN ) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Matt Kreps – Investor Relations Chas McKhann – Chief Executive Officer Jeff Black – Chief Financial Officer Conference Call Participants Mathew Blackman – Stifel Matt Hewitt – Craig-Hallum Capital Frank Takkinen – Lake Street Capital Josh Jennings – Cowen Simran Kaur – Piper Sandler Operator Good afternoon, ladies and gentlemen. And welcome to the Apollo Endosurgery Third Quarter 2022 Results Call.
2022-10-18 08:00:00 - Accesswire
Apollo Endosurgery to Report Third Quarter Results on November 1, 2022
AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m.
2022-08-08 02:37:02 - Seeking Alpha
Apollo Endosurgery, Inc. (APEN) CEO Chas McKhann on Q2 2022 Results - Earnings Call Transcript
Apollo Endosurgery, Inc. (NASDAQ:APEN ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Matt Kreps - Investor Relations Chas McKhann - Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Chris Cooley - Stephens Simran Kaur - Piper Sandler Frank Takkinen - Lake Street Capital Matt Hewitt - Craig-Hallum Capital Operator Good afternoon, ladies and gentlemen and welcome to Apollo Endosurgery Second Quarter 2022 Results. At this time all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.
2022-08-04 04:45:36 - Seeking Alpha
Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings
Apollo Endosurgery came in with another strong quarter of top-line growth whilst growing gross margins on the same. The company saw substantial growth in each of its key segments, coupled with regulatory momentum in its Apollo ESG and REVISE series.
2022-07-21 08:00:00 - Accesswire
Apollo Endosurgery to Report Second Quarter Results on August 2, 2022
AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m.
2022-07-13 16:15:26 - PennyStocks
Hot Penny Stocks to Watch Right Now? 3 For Your July List
Which penny stocks are you watching right now? The post Hot Penny Stocks to Watch Right Now?
2022-07-13 10:31:03 - Benzinga
Apollo Endosurgery's New Obesity Endoscopic Systems Receive FDA Nod
Apollo Endosurgery Inc (NASDAQ: APEN) announced the marketing authorization of the Apollo ESG, Apollo ESG Sx, Apollo REVISE, and Apollo REVISE Sx Systems through the FDA De Novo Classification process. The process is a premarket review pathway for low-to moderate-risk devices.